The inhibitory effect of suramin on telomerase activity and spheroid growth of C6 glioma cells

Background: The significant roles of telomerase in carcinogenesis and drug resistance have attracted growing attention as potential therapies. The aim of the study was to investigate the effect of suramin on the telomerase activity of C6 glioma cells and on the growth of C6 glioma spheroids

Increased P wave dispersion in hypothyroidism: a sign of risk of atrial fibrillation

Bilir, Cemil/0000-0002-1372-4791WOS: 000271094700020Aim: As in hyperthyroidism, cardiac arrhythmias can be seen in hypothyroidism. In this study, we measured P wave dispersion among hypothyroid patients to evaluate atrial fibrillation risk. Methods: 75 patients who received first time diagnosis of hypothyroidism and 40 normal control patients were included in this study. Each patient had echocardiographic and electrocardiographic studies were carried out. Groups were compared for statistically significant difference in P wave dispersion, minimum P wave duration and maximum P wave duration. Results: The groups were similar in echocardiographic and electrocardiograpic features. P wave dispersion was significantly higher in the hypothyroid group compared to normal controls (31.9 +/- 9.3 ms vs. 26.5 +/- 9.4 ms, p = 0.003). Minimum P wave duration was significantly shorter in the hypothyroid group compared to controls (63.8 +/- 9.2 ms vs 68 +/- 9.2ms, p = 0.026). Maximum P wave duration was not significantly different between groups (95.4 +/- 12.3 ms vs. 94.7 +/- 8.7 ms, p.0, 74). Conclusion: P wave dispersion was increased in the first time diagnosed clinical hypothyroid patients. This is the first study to evaluate P wave dispersion in clinical hypothyroid patients. We believe that our findings have clinically important implications and provide insight into possible mechanisms of this morbid condition

Increased P wave dispersion in hypothyroidism: a sign of risk of atrial fibrillation

Bilir, Cemil/0000-0002-1372-4791WOS: 000271094700020Aim: As in hyperthyroidism, cardiac arrhythmias can be seen in hypothyroidism. In this study, we measured P wave dispersion among hypothyroid patients to evaluate atrial fibrillation risk. Methods: 75 patients who received first time diagnosis of hypothyroidism and 40 normal control patients were included in this study. Each patient had echocardiographic and electrocardiographic studies were carried out. Groups were compared for statistically significant difference in P wave dispersion, minimum P wave duration and maximum P wave duration. Results: The groups were similar in echocardiographic and electrocardiograpic features. P wave dispersion was significantly higher in the hypothyroid group compared to normal controls (31.9 +/- 9.3 ms vs. 26.5 +/- 9.4 ms, p = 0.003). Minimum P wave duration was significantly shorter in the hypothyroid group compared to controls (63.8 +/- 9.2 ms vs 68 +/- 9.2ms, p = 0.026). Maximum P wave duration was not significantly different between groups (95.4 +/- 12.3 ms vs. 94.7 +/- 8.7 ms, p.0, 74). Conclusion: P wave dispersion was increased in the first time diagnosed clinical hypothyroid patients. This is the first study to evaluate P wave dispersion in clinical hypothyroid patients. We believe that our findings have clinically important implications and provide insight into possible mechanisms of this morbid condition

Is the thymidine labeling index a good prognostic marker in breast cancer?

Abstract Background The aim of the present study was to determine the prognostic relevance of thymidine labeling index (TLI) in patients with breast cancer. Methods TLI of the primary tumor was measured in 268 patients at the time of the surgical biopsy by an in vitro method. Results Fifty-four patients had stage I disease, and 138 patients had stage II disease, and 76 patients had stage III disease. One hundred-four patients were found to have low TLI-index ( Conclusion Our findings suggest that the prognostic significance of TLI appears to be limited to early breast cancer that might help to distinguish patients who need more aggressive adjuvant treatment.</p

Resveratrol attenuates doxorubicin-induced cellular damage by modulating nitric oxide and apoptosis

Although doxorubicin (DOX) is a commonly used chemotherapeutic agent its clinical use is restricted due to its organ toxicities. The present investigation relates to reducing DOX induced side effects to the liver, kidney and ileum by usage of the antioxidant, anti-inflammatory agent, resveratrol (RES) and to investigate the role of nitric oxide synthase (NOS) in the process. Wistar rats were divided into four groups: control (saline i.p); DOX (20 mg/kg i.p), RES (20 mg/kg i.p) and DOX (20 mg/kg i.p) + RES (20 mg/kg i.p). Immunohistochemical activity of both iNOS and eNOS were evaluated after DOX treatment and ultrastructural changes such as cellular damage and mitochondrial degeneration were evaluated. Degenerative ultrastructural changes were demonstrated especially in the DOX treated group. Variations in biochemical marker levels of oxidative stress on ischemia in tissues were not observed. Our data indicate that RES may prevent cellular damage in the early phase of DOX induced toxicity. RES could be used with its beneficial effects during early cellular damage in organ toxicity after DOX treatment in cancer patients. (C) 2010 Published by Elsevier GmbH

Endometrial Staining of CD56 (Uterine Natural Killer), BCL-6, and CD138 (Plasma Cells) Improve Diagnosis and Clinical Pregnancy Outcomes in Unexplained Infertility and Recurrent IVF Failures: Standardization of Diagnosis with Digital Pathology

In women with unexplained infertility (UI) and recurrent in vitro fertilization (IVF) failures, the etiology is often unclear. Endometrial immune perturbations and the use of immune markers associated with these dysregulations are of great interest in the diagnosis and treatment of UI. However, reliable biomarkers and standardized quantification methods are lacking. Here, to address endometrial immune dysregulation in UI patients with recurrent IVF failures, we performed endometrial tissue sampling and immunostaining of CD56 (uNK), CD138, and BCL-6. Of these cases, 57.9% had positive CD56 in the endometrial stroma, while 46.1% had positive BCL-6 in the glandular epithelium, and 14.5% of the cases were found to be positive for CD138. Combined staining rates were 60.5%, 68.4%, and 71.05% for (CD56 or BCL-6), (CD56 or CD138), and (CD56, BCL-6, or CD138), respectively. There was a significant correlation between CD56 and BCL-6 positivity, while CD138 positivity was an independent parameter. After the recommended targeted therapy, pregnancy rates were found to increase from 58.5% to 61.6% and 73.8% in CD56-positive, (CD56- or BCL-6-positive), and (CD56-, BCL-6-, or CD138-positive) cases, respectively. Notably, a retrospective evaluation of digital pathology and light microscopy results showed a significant correlation. This study suggests that the examination of CD56, BCL-6, and CD138 in the same endometrial sample may be an effective method in determining the etiology of UI and reaching an early diagnosis and treatment options. Moreover, digital pathology can be used in the evaluation of CD56 and BCL-6 to provide objective, rapid, and reliable results